Approvals, financings, and platform shifts across six beats, and what each one means for the decision in front of you. Written for founders, investors, and operators who need the read before the market has one.
Get the brief
Free. Takes about five minutes to read.
A single brief covering what moved across all six beats. No daily alerts and no drip sequence.
After your email, you can choose which beats matter most to you. Skip it and you get everything.
No paywall and no cost. Every email has a one-click unsubscribe, and we do not sell your address.
Aspen is using fresh clinical momentum around its Parkinson’s cell therapy sasineprocel to support a public-market move, while Bambusa is pitching a bispecific inflammation portfolio led by BBT001 in atopic dermatitis. The pair show that investors are still being asked to fund very different risk profiles, from a planned phase 3 launch to broad early clinical expansion.
The source describes Lilly as having pulled ahead of Novo in GLP-1s, with Zepbound and Mounjaro generating more than $35 billion last year. It also points to more than $30 billion in 2026 biotech buyouts and new China-focused deals as evidence that Lilly is using current cash flow to widen its future options.
Abuzaina most recently served as Worldwide VP/GM, Advanced Repair and Reconstruction, within Surgery, and will report to Peter Menziuso, Executive Vice President and President of BD’s Interventional segment. The move points to continuity rather than a strategic reset in a business BD says is entering its next chapter of growth.
ARM’s framework centers on identifying which parts of a platform stay fixed across programs and which product-specific elements still need fresh evidence. The strategic signal is that gene-editing developers are now pushing to turn platform logic into a practical regulatory and cost structure, especially for diseases too small to support traditional development budgets.
According to STAT’s summary of Nancy Krieger’s essay, the Trump administration wants to eliminate questions about race, ethnicity, and sexual orientation, exclude anyone who is not a citizen or lawful permanent resident, and change how residence is determined for groups such as college students and retiree snowbirds. The policy signal is that changes to basic population counting can reshape both epidemiology and the flow of public resources.